Role of the gut microbiome in obesity and diabetes mellitus

Nutrition in Clinical Practice

Volumn 30, Issue 6, 2015, Pages 787-797

  Barlow, Gillian M ^a   Yu, Allen ^a   Mathur, Ruchi ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

diabetes mellitus; mechanisms; Methanobrevibacter smithii; methanogens; microbiome; microbiota; obesity

Indexed keywords

BILE ACID; BUTYRIC ACID; POLYSACCHARIDE;

BACTEROIDETES; DIETARY INTAKE; ENVIRONMENTAL FACTOR; FAECALIBACTERIUM PRAUSNITZII; FIRMICUTES; GAMMAPROTEOBACTERIA; GASTROINTESTINAL ABSORPTION; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; LIPOGENESIS; METHANOGENIC ARCHAEON; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRIENT; OBESITY; REVIEW; RODENT MODEL; SMALL INTESTINE; VERRUCOMICROBIA; WEIGHT GAIN; MICROBIOLOGY;

DIABETES MELLITUS, TYPE 2; GASTROINTESTINAL MICROBIOME; HUMANS; OBESITY;

EID: 84946735472     PISSN: 08845336     EISSN: 19412452     Source Type: Journal    
DOI: 10.1177/0884533615609896     Document Type: Review

References (161)

1. World Health Organization. Physical Status: The Use and Interpretation of Anthropometry. Report of a WHO Expert Committee. Geneva, Switzerland: World Health Organization; 1995.
2. World Health Organization. Obesity: Preventing and Managing the Global Epidemic. Report of a WHO Consultation on Obesity, 3-5 June 1997. Geneva, Switzerland: World Health Organization; 1998.
3. World Health Organization. Obesity: Preventing and Managing the Global Epidemic. Report of a WHO Consultation. Geneva, Switzerland: World Health Organization; 2000.
4. Haslam DW, James WP,. Obesity. Lancet. 2005; 366: 1197-1209.
5. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ,. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003; 348: 1625-1638.
6. Wall M,. Idiopathic intracranial hypertension (pseudotumor cerebri). Curr Neurol Neurosci Rep. 2008; 8: 87-93.
7. Choi HK, Atkinson K, Karlson EW, Curhan G,. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med. 2005; 165: 742-748.
8. Malnick SD, Knobler H,. The medical complications of obesity. QJM. 2006; 99: 565-579.
9. Flegal KM, Graubard BI, Williamson DF, Gail MH,. Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA. 2007; 298: 2028-2037.
10. Orpana HM, Berthelot JM, Kaplan MS, Feeny DH, McFarland B, Ross NA,. BMI and mortality: results from a national longitudinal study of Canadian adults. Obesity (Silver Spring). 2010; 18: 214-218.
11. Withrow D, Alter DA,. The economic burden of obesity worldwide: a systematic review of the direct costs of obesity. Obes Rev. 2011; 12: 131-141.
12. Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M,. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet. 2011; 378: 815-825.
13. Cawley J, Meyerhoefer C, Biener A, Hammer M, Wintfeld N,. Savings in medical expenditures associated with reductions in body mass index among US adults with obesity, by diabetes status. Pharmacoeconomics. 2015; 33 (7): 707-722.
14. Li Q, Blume SW, Huang JC, Hammer M, Graf TR,. The economic burden of obesity by glycemic stage in the United States. Pharmacoeconomics. 2015; 33 (7): 735-748.
15. World Health Organization. Obesity and Overweight. Geneva, Switzerland: World Health Organization; 2015.
16. World Health Organization. Diabetes. Geneva, Switzerland: World Health Organization; 2015.
17. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H,. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia. 2001; 44 (suppl 2): S14-S21.
18. Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta, GA: Centers for Disease Control and Prevention; 2014.
19. Weinsier RL, Hunter GR, Heini AF, Goran MI, Sell SM,. The etiology of obesity: relative contribution of metabolic factors, diet, and physical activity. Am J Med. 1998; 105: 145-150.
20. The gut microbiota. Science. 2012; 336 (special issue).
21. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature. 2012; 486: 207-214.
22. Human Microbiome Project Consortium. A framework for human microbiome research. Nature. 2012; 486: 215-221.
23. Savage DC,. Microbial ecology of the gastrointestinal tract. Annu Rev Microbiol. 1977; 31: 107-133.
24. Gill SR, Pop M, Deboy RT, et al. Metagenomic analysis of the human distal gut microbiome. Science. 2006; 312: 1355-1359.
25. Backhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI,. Host-bacterial mutualism in the human intestine. Science. 2005; 307: 1915-1920.
26. Blaser MJ, Falkow S,. What are the consequences of the disappearing human microbiota? Nat Rev Microbiol. 2009; 7: 887-894.
27. Russell SL, Gold MJ, Hartmann M, et al. Early life antibiotic-driven changes in microbiota enhance susceptibility to allergic asthma. EMBO Rep. 2012; 13: 440-447.
28. Sanz Y, Santacruz A, Gauffin P,. Gut microbiota in obesity and metabolic disorders. Proc Nutr Soc. 2010; 69: 434-441.
29. Cani PD, Everard A, Duparc T,. Gut microbiota, enteroendocrine functions and metabolism. Curr Opin Pharmacol. 2013; 13: 935-940.
30. Littman DR, Pamer EG,. Role of the commensal microbiota in normal and pathogenic host immune responses. Cell Host Microbe. 2011; 10: 311-323.
31. Salzman NH,. Microbiota-immune system interaction: an uneasy alliance. Curr Opin Microbiol. 2011; 14: 99-105.
32. Sahakian AB, Jee SR, Pimentel M,. Methane and the gastrointestinal tract. Dig Dis Sci. 2010; 55: 2135-2143.
33. Musso G, Gambino R, Cassader M,. Interactions between gut microbiota and host metabolism predisposing to obesity and diabetes. Ann Rev Med. 2011; 62: 361-380.
34. Sommer F, Backhed F,. The gut microbiota: masters of host development and physiology. Nat Rev Microbiol. 2013; 11: 227-238.
35. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI,. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006; 444: 1027-1031.
36. McNeil NI,. The contribution of the large intestine to energy supplies in man. Am J Clin Nutr. 1984; 39: 338-342.
37. Ridlon JM, Kang DJ, Hylemon PB,. Bile salt biotransformations by human intestinal bacteria. J Lipid Res. 2006; 47: 241-259.
38. Jones BV, Begley M, Hill C, Gahan CG, Marchesi JR,. Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome. Proc Natl Acad Sci U S A. 2008; 105: 13580-13585.
39. Hooper LV, Midtvedt T, Gordon JI,. How host-microbial interactions shape the nutrient environment of the mammalian intestine. Ann Rev Nutr. 2002; 22: 283-307.
40. Bäckhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A. 2004; 101: 15718-15723.
41. Conly JM, Stein K, Worobetz L, Rutledge-Harding S,. The contribution of vitamin K2 (menaquinones) produced by the intestinal microflora to human nutritional requirements for vitamin K. Am J Gastroenterol. 1994; 89: 915-923.
42. Hooper LV, Gordon JI,. Commensal host-bacterial relationships in the gut. Science. 2001; 292: 1115-1118.
43. Aagaard K, Ma J, Antony KM, Ganu R, Petrosino J, Versalovic J,. The placenta harbors a unique microbiome. Sci Transl Med. 2014; 6:237ra65.
44. Palmer C, Bik EM, DiGiulio DB, Relman DA, Brown PO,. Development of the human infant intestinal microbiota. PLoS Biol. 2007; 5: e177.
45. Koenig JE, Spor A, Scalfone N, et al. Succession of microbial consortia in the developing infant gut microbiome. Proc Natl Acad Sci U S A. 2011; 108 (suppl 1): 4578-4585.
46. Schloissnig S, Arumugam M, Sunagawa S, et al. Genomic variation landscape of the human gut microbiome. Nature. 2013; 493: 45-50.
47. Yatsunenko T, Rey FE, Manary MJ, et al. Human gut microbiome viewed across age and geography. Nature. 2012; 486: 222-227.
48. Claesson MJ, Jeffery IB, Conde S, et al. Gut microbiota composition correlates with diet and health in the elderly. Nature. 2012; 488: 178-184.
49. O'Sullivan O, Coakley M, Lakshminarayanan B, et al. Alterations in intestinal microbiota of elderly Irish subjects post-antibiotic therapy. J Antimicrob Chemother. 2013; 68: 214-221.
50. Peterson J, Garges S, Giovanni M, et al. The NIH Human Microbiome Project. Genome Res. 2009; 19: 2317-2323.
51. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010; 464: 59-65.
52. Sears CL,. A dynamic partnership: celebrating our gut flora. Anaerobe. 2005; 11: 247-251.
53. Weaver GA, Krause JA, Miller TL, Wolin MJ,. Incidence of methanogenic bacteria in a sigmoidoscopy population: an association of methanogenic bacteria and diverticulosis. Gut. 1986; 27: 698-704.
54. Pochart P, Lemann F, Flourie B, Pellier P, Goderel I, Rambaud JC,. Pyxigraphic sampling to enumerate methanogens and anaerobes in the right colon of healthy humans. Gastroenterology. 1993; 105: 1281-1285.
55. Miller TL, Wolin MJ,. Enumeration of Methanobrevibacter smithii in human feces. Arch Microbiol. 1982; 131: 14-18.
56. Gaci N, Borrel G, Tottey W, O'Toole PW, Brugere JF,. Archaea and the human gut: new beginning of an old story. World J Gastroenterol. 2014; 20: 16062-16078.
57. Scanlan PD, Shanahan F, Marchesi JR,. Human methanogen diversity and incidence in healthy and diseased colonic groups using mcrA gene analysis. BMC Microbiol. 2008; 8: 79.
58. Mihajlovski A, Dore J, Levenez F, Alric M, Brugere JF,. Molecular evaluation of the human gut methanogenic archaeal microbiota reveals an age-associated increase of the diversity. Environ Microbiol Rep. 2010; 2: 272-280.
59. Nava GM, Carbonero F, Croix JA, Greenberg E, Gaskins HR,. Abundance and diversity of mucosa-associated hydrogenotrophic microbes in the healthy human colon. ISME J. 2012; 6: 57-70.
60. O'Hara AM, Shanahan F,. The gut flora as a forgotten organ. EMBO Rep. 2006; 7: 688-693.
61. Sekirov I, Russell SL, Antunes LC, Finlay BB,. Gut microbiota in health and disease. Physiol Rev. 2010; 90: 859-904.
62. Pyleris E, Giamarellos-Bourboulis EJ, Tzivras D, Koussoulas V, Barbatzas C, Pimentel M,. The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome. Dig Dis Sci. 2012; 57: 1321-1329.
63. Giamarellos-Bourboulis E, Tang J, Pyleris E, et al. Molecular assessment of differences in the duodenal microbiome in subjects with irritable bowel syndrome. Scand J Gastroenterol. 2015; 50 (9): 1076-1087.
64. Tyakht AV, Kostryukova ES, Popenko AS, et al. Human gut microbiota community structures in urban and rural populations in Russia. Nat Commun. 2013; 4: 2469.
65. Li J, Jia H, Cai X, et al. An integrated catalog of reference genes in the human gut microbiome. Nat Biotechnol. 2014; 32: 834-841.
66. Manichanh C, Rigottier-Gois L, Bonnaud E, et al. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut. 2006; 55: 205-211.
67. Durban A, Abellan JJ, Jimenez-Hernandez N, et al. Instability of the faecal microbiota in diarrhoea-predominant irritable bowel syndrome. FEMS Microbiol Ecol. 2013; 86: 581-589.
68. Ahn J, Sinha R, Pei Z, et al. Human gut microbiome and risk for colorectal cancer. J Natl Cancer Inst. 2013; 105: 1907-1911.
69. Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A. 2008; 105: 16731-16736.
70. Kerckhoffs AP, Samsom M, van der Rest ME, et al. Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. World J Gastroenterol. 2009; 15: 2887-2892.
71. Kerckhoffs AP, Visser MR, Samsom M, et al. Critical evaluation of diagnosing bacterial overgrowth in the proximal small intestine. J Clin Gastroenterol. 2008; 42: 1095-1102.
72. Ghoshal UC, Shukla R, Ghoshal U, Gwee KA, Ng SC, Quigley EM,. The gut microbiota and irritable bowel syndrome: friend or foe? Int J Inflam. 2012; 2012: 151085.
73. Abu-Shanab A, Quigley EM,. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2010; 7: 691-701.
74. Mouzaki M, Comelli EM, Arendt BM, et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology. 2013; 58: 120-127.
75. Cani PD, Bibiloni R, Knauf C, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008; 57: 1470-1481.
76. Cani PD, Delzenne NM,. The gut microbiome as therapeutic target. Pharmacol Ther. 2011; 130: 202-212.
77. DiBaise JK, Zhang H, Crowell MD, Krajmalnik-Brown R, Decker GA, Rittmann BE,. Gut microbiota and its possible relationship with obesity. Mayo Clin Proc. 2008; 83: 460-469.
78. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007; 56: 1761-1772.
79. Backhed F, Manchester JK, Semenkovich CF, Gordon JI,. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A. 2007; 104: 979-984.
80. Schwiertz A, Taras D, Schafer K, et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity (Silver Spring). 2010; 18: 190-195.
81. Zhang C, Zhang M, Wang S, et al. Interactions between gut microbiota, host genetics and diet relevant to development of metabolic syndromes in mice. ISME J. 2010; 4: 232-241.
82. Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI,. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A. 2005; 102: 11070-11075.
83. Ley RE, Turnbaugh PJ, Klein S, Gordon JI,. Microbial ecology: human gut microbes associated with obesity. Nature. 2006; 444: 1022-1023.
84. Zhang H, DiBaise JK, Zuccolo A, et al. Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci U S A. 2009; 106: 2365-2370.
85. Furet JP, Kong LC, Tap J, et al. Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes. 2010; 59: 3049-3057.
86. Graessler J, Qin Y, Zhong H, et al. Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters. Pharmacogenomics J. 2013; 13: 514-522.
87. Larsen N, Vogensen FK, van den Berg FW, et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One. 2010; 5: e9085.
88. Qin J, Li Y, Cai Z, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012; 490: 55-60.
89. Karlsson FH, Tremaroli V, Nookaew I, et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature. 2013; 498: 99-103.
90. Zhang X, Shen D, Fang Z, et al. Human gut microbiota changes reveal the progression of glucose intolerance. PLoS One. 2013; 8: e71108.
91. Liou AP, Paziuk M, Luevano JM Jr, Machineni S, Turnbaugh PJ, Kaplan LM,. Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci Transl Med. 2013; 5:178ra41.
92. Sankar SA, Lagier JC, Pontarotti P, Raoult D, Fournier PE,. The human gut microbiome, a taxonomic conundrum. Syst Appl Microbiol. 2015; 38: 276-286.
93. Rhodes JM, Middleton P, Jewell DP,. The lactulose hydrogen breath test as a diagnostic test for small-bowel bacterial overgrowth. Scand J Gastroenterol. 1979; 14: 333-336.
94. Stewart JA, Chadwick VS, Murray A,. Carriage, quantification, and predominance of methanogens and sulfate-reducing bacteria in faecal samples. Lett Appl Microbiol. 2006; 43: 58-63.
95. Dridi B, Henry M, El Khechine A, Raoult D, Drancourt M,. High prevalence of Methanobrevibacter smithii and Methanosphaera stadtmanae detected in the human gut using an improved DNA detection protocol. PLoS One. 2009; 4: e7063.
96. Kim G, Giamarellos-Bourboulis EJ, Chang C, Pyleris E, Pistiki K, Pimentel M,. Quantitation of bacteria in duodenal aspirates by qPCR appears to identify viable organisms in IBS gastroenterology. 2013; 144:S-908.
97. Kunkel D, Basseri RJ, Makhani MD, Chong K, Chang C, Pimentel M,. Methane on breath testing is associated with constipation: a systematic review and meta-analysis. Dig Dis Sci. 2011; 56: 1612-1618.
98. Triantafyllou K, Chang C, Pimentel M,. Methanogens, methane and gastrointestinal motility. J Neurogastroenterol Motil. 2014; 20: 31-40.
99. Levitt MD, Furne JK, Kuskowski M, Ruddy J,. Stability of human methanogenic flora over 35 years and a review of insights obtained from breath methane measurements. Clin Gastroenterol Hepatol. 2006; 4: 123-129.
100. McKay LF, Eastwood MA, Brydon WG,. Methane excretion in man: a study of breath, flatus, and faeces. Gut. 1985; 26: 69-74.
101. Hudson MJ, Tomkins AM, Wiggins HS, Drasar BS,. Breath methane excretion and intestinal methanogenesis in children and adults in rural Nigeria. Scand J Gastroenterol. 1993; 28: 993-998.
102. Kim G, Deepinder F, Morales W, et al. Methanobrevibacter smithii is the predominant methanogen in patients with constipation-predominant IBS and methane on breath. Dig Dis Sci. 2012; 57: 3213-3218.
103. Samuel BS, Gordon JI,. A humanized gnotobiotic mouse model of host-archaeal-bacterial mutualism. Proc Natl Acad Sci U S A. 2006; 103: 10011-10016.
104. Armougom F, Henry M, Vialettes B, Raccah D, Raoult D,. Monitoring bacterial community of human gut microbiota reveals an increase in Lactobacillus in obese patients and Methanogens in anorexic patients. PLoS One. 2009; 4: e7125.
105. Patil DP, Dhotre DP, Chavan SG, et al. Molecular analysis of gut microbiota in obesity among Indian individuals. J Biosci. 2012; 37: 647-657.
106. Million M, Maraninchi M, Henry M, et al. Obesity-associated gut microbiota is enriched in Lactobacillus reuteri and depleted in Bifidobacterium animalis and. Methanobrevibacter smithii. Int J Obes. 2012; 36: 817-825.
107. Million M, Angelakis E, Maraninchi M, et al. Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibacter smithii and. Escherichia coli. Int J Obes (Lond). 2013; 37 (11): 1460-1466.
108. Basseri RJ, Basseri B, Pimentel M, et al. Intestinal methane production in obese individuals is associated with a higher body mass index. Gastroenterol Hepatol. 2012; 8: 22-28.
109. Mathur R, Amichai M, Chua KS, Mirocha J, Barlow GM, Pimentel M,. Methane and hydrogen positivity on breath test is associated with greater body mass index and body fat. J Clin Endocrinol Metab. 2013; 98: E698-E702.
110. Mathur R, Goyal D, Kim G, Barlow GM, Chua KS, Pimentel M,. Methane-producing human subjects have higher serum glucose levels during oral glucose challenge than non-methane producers: a pilot study of the effects of enteric methanogens on glycemic regulation. Research Journal of Endocrinology and Metabolism. 2014; 2: 1-5.
111. Cesario V, Di Rienzo TA, Campanale M, et al. Methane intestinal production and poor metabolic control in type I diabetes complicated by autonomic neuropathy. Minerva Endocrinol. 2014; 39: 201-207.
112. Tremaroli V, Backhed F,. Functional interactions between the gut microbiota and host metabolism. Nature. 2012; 489: 242-249.
113. Tolhurst G, Heffron H, Lam YS, et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes. 2012; 61: 364-371.
114. Lin HV, Frassetto A, Kowalik EJ Jr, et al. Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. PLoS One. 2012; 7: e35240.
115. Samuel BS, Shaito A, Motoike T, et al. Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. Proc Natl Acad Sci U S A. 2008; 105: 16767-16772.
116. Kimura I, Ozawa K, Inoue D, et al. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat Commun. 2013; 4: 1829.
117. Maslowski KM, Vieira AT, Ng A, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature. 2009; 461: 1282-1286.
118. Ulven T,. Short-chain free fatty acid receptors FFA2/GPR43 and FFA3/GPR41 as new potential therapeutic targets. Front Endocrinol (Lausanne). 2012; 3: 111.
119. Bjursell M, Admyre T, Goransson M, et al. Improved glucose control and reduced body fat mass in free fatty acid receptor 2-deficient mice fed a high-fat diet. Am J Physiol Endocrinol Metab. 2011; 300: E211-E220.
120. Bellahcene M, O'Dowd JF, Wargent ET, et al. Male mice that lack the G-protein-coupled receptor GPR41 have low energy expenditure and increased body fat content. Br J Nutr. 2013; 109: 1755-1764.
121. Brahe LK, Astrup A, Larsen LH,. Is butyrate the link between diet, intestinal microbiota and obesity-related metabolic diseases? Obes Rev. 2013; 14: 950-959.
122. Inan MS, Rasoulpour RJ, Yin L, Hubbard AK, Rosenberg DW, Giardina C,. The luminal short-chain fatty acid butyrate modulates NF-kappaB activity in a human colonic epithelial cell line. Gastroenterology. 2000; 118: 724-734.
123. Segain JP, Raingeard de la Bletiere D, Bourreille A, et al. Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut. 2000; 47: 397-403.
124. Luhrs H, Gerke T, Schauber J, et al. Cytokine-activated degradation of inhibitory kappaB protein alpha is inhibited by the short-chain fatty acid butyrate. Int J Colorectal Dis. 2001; 16: 195-201.
125. Luhrs H, Gerke T, Muller JG, et al. Butyrate inhibits NF-kappaB activation in lamina propria macrophages of patients with ulcerative colitis. Scand J Gastroenterol. 2002; 37: 458-466.
126. Hamer HM, Jonkers DM, Bast A, et al. Butyrate modulates oxidative stress in the colonic mucosa of healthy humans. Clin Nutr. 2009; 28: 88-93.
127. Vrieze A, Van Nood E, Holleman F, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012; 143: 913-6.e7.
128. Creely SJ, McTernan PG, Kusminski CM, et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab. 2007; 292: E740-E747.
129. Erridge C, Attina T, Spickett CM, Webb DJ,. A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr. 2007; 86: 1286-1292.
130. Cani PD, Neyrinck AM, Fava F, et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia. 2007; 50: 2374-2383.
131. Brun P, Castagliuolo I, Di Leo V, et al. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol. 2007; 292: G518-G525.
132. Saberi M, Woods NB, de Luca C, et al. Hematopoietic cell-specific deletion of Toll-like receptor 4 ameliorates hepatic and adipose tissue insulin resistance in high-fat-fed mice. Cell Metabol. 2009; 10: 419-429.
133. Poggi M, Bastelica D, Gual P, et al. C3H/HeJ mice carrying a Toll-like receptor 4 mutation are protected against the development of insulin resistance in white adipose tissue in response to a high-fat diet. Diabetologia. 2007; 50: 1267-1276.
134. Vijay-Kumar M, Aitken JD, Carvalho FA, et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science. 2010; 328: 228-231.
135. Muccioli GG, Naslain D, Backhed F, et al. The endocannabinoid system links gut microbiota to adipogenesis. Mol Syst Biol. 2010; 6: 392.
136. Willemsen LE, Koetsier MA, van Deventer SJ, van Tol EA,. Short chain fatty acids stimulate epithelial mucin 2 expression through differential effects on prostaglandin E(1) and E(2) production by intestinal myofibroblasts. Gut. 2003; 52: 1442-1447.
137. Cani PD, Possemiers S, Van de Wiele T, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut. 2009; 58: 1091-1103.
138. Hansen TH, Gobel RJ, Hansen T, Pedersen O,. The gut microbiome in cardio-metabolic health. Genome Med. 2015; 7: 33.
139. Watanabe M, Houten SM, Wang L, et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest. 2004; 113: 1408-1418.
140. Watanabe M, Houten SM, Mataki C, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature. 2006; 439: 484-489.
141. Prawitt J, Abdelkarim M, Stroeve JH, et al. Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity. Diabetes. 2011; 60: 1861-1871.
142. Fang S, Suh JM, Reilly SM, et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nature Med. 2015; 21: 159-165.
143. Renga B, Mencarelli A, Vavassori P, Brancaleone V, Fiorucci S,. The bile acid sensor FXR regulates insulin transcription and secretion. Biochim Biophys Acta. 2010; 1802: 363-372.
144. Popescu IR, Helleboid-Chapman A, Lucas A, et al. The nuclear receptor FXR is expressed in pancreatic beta-cells and protects human islets from lipotoxicity. FEBS Lett. 2010; 584: 2845-2851.
145. Schittenhelm B, Wagner R, Kahny V, et al. Role of FXR in beta-cells of lean and obese mice. Endocrinology. 2015; 156: 1263-1271.
146. Thomas C, Gioiello A, Noriega L, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 2009; 10: 167-177.
147. Kobayashi M, Ikegami H, Fujisawa T, et al. Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin. Diabetes. 2007; 56: 239-247.
148. Suzuki T, Oba K, Igari Y, et al. Effects of bile-acid-binding resin (colestimide) on blood glucose and visceral fat in Japanese patients with type 2 diabetes mellitus and hypercholesterolemia: an open-label, randomized, case-control, crossover study. J Diabetes Complications. 2012; 26: 34-39.
149. Yamakawa T, Takano T, Utsunomiya H, Kadonosono K, Okamura A,. Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia. Endocr J. 2007; 54: 53-58.
150. Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR,. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care. 2008; 31: 1479-1484.
151. Rosenstock J, Truitt KE, Baz-Hecht M, Ford DM, Tao B, Chou HS,. Efficacy and safety of colesevelam in combination with pioglitazone in patients with type 2 diabetes mellitus. Horm Metab Res. 2014; 46: 943-949.
152. Seeley RJ, Chambers AP, Sandoval DA,. The role of gut adaptation in the potent effects of multiple bariatric surgeries on obesity and diabetes. Cell Metab. 2015; 21: 369-378.
153. Jones WJ, Nagle DP Jr, Whitman WB,. Methanogens and the diversity of archaebacteria. Microbiol Rev. 1987; 51: 135-177.
154. McKay LF, Holbrook WP, Eastwood MA,. Methane and hydrogen production by human intestinal anaerobic bacteria. Acta Pathol Microbiol Immunol Scand B. 1982; 90: 257-260.
155. Gibson GR, Cummings JH, Macfarlane GT, et al. Alternative pathways for hydrogen disposal during fermentation in the human colon. Gut. 1990; 31: 679-683.
156. Krajmalnik-Brown R, Ilhan ZE, Kang DW, DiBaise JK,. Effects of gut microbes on nutrient absorption and energy regulation. Nutr Clin Pract. 2012; 27: 201-214.
157. Bauchop T, Mountfort DO,. Cellulose fermentation by a rumen anaerobic fungus in both the absence and the presence of rumen methanogens. Appl Environ Microbiol. 1981; 42: 1103-1110.
158. Pimentel M, Lin HC, Enayati P, et al. Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity. Am J Physiol Gastrointest Liver Physiol. 2006; 290: G1089-G1095.
159. Jahng J, Jung IS, Choi EJ, Conklin JL, Park H,. The effects of methane and hydrogen gases produced by enteric bacteria on ileal motility and colonic transit time. Neurogastroenterol Motil. 2012; 24: 185-190, e92.
160. Parkman HP, Yates K, Hasler WL, et al. Clinical features of idiopathic gastroparesis vary with sex, body mass, symptom onset, delay in gastric emptying, and gastroparesis severity. Gastroenterology. 2011; 140: 101-115.
161. Kunkel D, Basseri B, Low K, et al. Efficacy of the glucagon-like peptide-1 agonist exenatide in the treatment of short bowel syndrome. Neurogastroenterol Motil. 2011; 23 (8): 739-e328.